Showing 4091-4100 of 6661 results for "".
- Burt's Bees Sensitive Skincare Line Awarded National Eczema Association Seal of Acceptancehttps://practicaldermatology.com/news/burts-bees-sensitive-skincare-line-awarded-national-eczema-association-seal-of-acceptance/2457892/The National Eczema Society (NEA) has awarded Burt's Bees' Sensitive skin care line the NEA's Seal of Acceptance, which maintains rigorous standards for approval. The Sensitive skin care line includes Burt's Bees Sensitive Facial Cleanser, Burt's Bees Sensitive Eye Cream, Burt
- FDA Approves Cosentyx Label Update to Include Scalp Psoriasishttps://practicaldermatology.com/news/fda-approves-cosentyx-label-update-to-include-scalp-psoriasis/2457896/The FDA has approved a label update for Novartis' Cosentyx (secukinumab), the first interleukin-17A (IL-17A) antagonist approved to treat moderate to severe plaque psoriasis. The updated label includes Cosentyx data in moderate to severe scalp psoriasis—one of the difficult-to-treat for
- Research Finds Acne Linked with Increased Risk of Depressionhttps://practicaldermatology.com/news/research-finds-acne-linked-with-increased-risk-of-depression/2457898/In an analysis of one of the largest electronic medical records databases in the world, researchers found that patients with acne had a significantly increased risk of developing major depression, but only in the first 5 years after being diagnosed with acne.
- Short Course Radiation Best Longer Courses in Older Skin Cancer Patientshttps://practicaldermatology.com/news/short-case-radiation-best-longer-courses-in-older-skin-cancer-patients/2457899/Shorter courses of radiation seem to be better than longer ones for older patients receiving treatment for basal and squamous cell skin cancers, a recent Penn State College of Medicine physician’s st
- eRelevance Adds Two to Executive Leadership Teamhttps://practicaldermatology.com/news/erelevance-adds-two-to-executive-leadership-team/2457901/eRelevance has added two new names to its executive leadership team. Rafael Landestoy is now vice president of business development and Travis Skidmore is vice president of client success and retention. Mr. Landestoy will lead eRelevance&nbs
- Dove Launches DermaSeries Product Line for Dry Skin Plus Companion Campaignhttps://practicaldermatology.com/news/dove-launches-dermaseries-product-line-for-dry-skin-plus-companion-campaign/2457904/Dove is rolling out NEW Dove DermaSeries, a completely hypoallergenic and fragrance-free range of cleansers and lotions formulated especially for the driest skin. A companion campaign --
- Intraderm Changes Alevicyn Product Name to Levicynhttps://practicaldermatology.com/news/intraderm-changes-alevicyn-product-name-to-levicyn/2457910/Intraderm's Alevicyn is getting a new name—Levicyn. The Gel formulation is now Levicyn Antipruritic Gel, the Spray Gel is now Levicyn Antipruritic SG, and the Dermal Spray is now Levicyn Antimicrobial Dermal Spray. The company notes that physicians can still write for Alevicyn d
- Revision to Launch Intellishade TruPhysicalhttps://practicaldermatology.com/news/revision-to-launch-intellishade-truphysical/2457912/Revision Skincare will be launching Intellishade® TruPhysical™, formulated with a proprietary blend of over 20 age-defying ingredients. The four-in-one moisturizer helps to correct, protect, hydrate and shield skin for a brighter, smoother complexion. According to
- Research Elucidates LIGHT's Role in ADhttps://practicaldermatology.com/news/research-elucidates-lights-role-in-ad/2457919/LIGHT, a member of the tumor necrosis factor (TNF) super family, directly controls the hyperproliferation of keratinocytes as well as the expression of periostin, a protein that contributes to the clinical features of atopic dermatitis and other inflammatory skin diseases such as scleroderma, rep
- FDA Accepts Ortho Dermatologics' Filing for IDP-121 Acne Treatment In Lotion Formhttps://practicaldermatology.com/news/fda-accepts-ortho-dermatologics-filing-for-idp-121-acne-treatment-in-lotion-form/2457925/The FDA has accepted Ortho Dermatologics' New Drug Application for IDP-121 (tretinoin 0.05%) lotion (Altreno) with a PDUFA action date of Aug. 27, 2018. If approved, Altreno will be the first tretinoin product in lotion form rather than a gel or cream.